How ASX-listed pharma companies rebuild boards after leadership churn
Synopsis
Mayne Pharma’s board overhaul following its failed takeover highlights how ASX-listed pharmaceutical companies rebuild leadership, restore governance and reposition for long-term growth after major executive departures.
Count the departures at Mayne Pharma and you start to appreciate the scale of what the company has been through. In the space of five months, the specialty drugmaker lost its chairman, two long-serving non-executive directors, its chief executive and, a little later, another director. The share price that once carried a $7.40 takeover offer was trading below $3. For a business that spent most of 2025 fighting to be acquired, the story of 2026 has become something else entirely: how you rebuild a board when the deal that was meant to define your future falls apart.
Mayne is worth studying closely because leadership churn on the ASX rarely arrives on its own. It tends to follow a shock, a failed transaction, a strategic reset, a governance blow-up and the way a board reconstitutes itself afterwards tells shareholders far more than any glossy strategy update. The appointments are the signal. You just have to know how to read them.
The shock that started it
The churn at Mayne wasn't spontaneous. It was the aftershock of one of the most bruising takeover disputes the local market has seen in years.
In February 2025, US private-equity-backed Cosette Pharmaceuticals agreed to buy Mayne for $7.40 a share, valuing the company at roughly $672 million. Within months the deal was in open warfare. Cosette tried to walk, claiming a material adverse change on the back of softer earnings and an FDA warning letter over promotional material. Mayne refused to let go. In October, the NSW Supreme Court sided with the target, ruling that Cosette had not validly terminated and, tellingly, had affirmed the contract through its own conduct. It was a landmark judgment on how MAC clauses actually work in this country.
Winning in court, however, is not the same as getting your money. Cosette had already told the Foreign Investment Review Board it might close Mayne's profitable Salisbury manufacturing plant in South Australia, a facility carrying more than 200 jobs, recent upgrades and government grants. The South Australian government intervened. On 21 November, Treasurer Jim Chalmers blocked the transaction on national interest grounds, citing risks to critical medicine supply. The deal was dead. By December, Mayne had flipped the table, issuing its own termination notice and alleging wilful breaches, with a $6.72 million break fee and possible damages still to be fought over.
Shareholders were left holding a standalone company worth less than half the offer price, and a register nursing heavy paper losses. That is the environment into which a board rebuild lands: not a blank page, but a crime scene.
Reading the appointments
What Mayne did next followed a pattern that recurs across the ASX whenever a company has to steady itself in a hurry.
The first move was continuity at the top. Long-serving chairman Frank Condella retired in mid-January, and the board handed the chair to Bruce Robinson, a director since 2014, a practising endocrinologist, a former dean of Sydney's medical school and a sitting non-executive director of Cochlear. This is a familiar reflex. When a company is under pressure, boards reach for the insider who knows where the bodies are buried rather than an outsider who needs a year to find the light switches. Robinson's message to shareholders at the January annual meeting was pointedly plain-spoken. He told the meeting he was aware none of them would be happy with the share price, and framed the Treasurer's decision and Cosette's conduct as beyond the company's control. Boards that survive strikes tend to lead with that kind of candour.
The second move was execution over reinvention. Chief executive Shawn O'Brien, who had run the company through the entire Cosette ordeal, stepped down in February, with chief financial officer Aaron Gray elevated into the top job. Promoting the CFO is a deliberate signal in itself. It tells the market the board wants financial discipline and continuity of strategy, not a fresh vision that would take another eighteen months to articulate. O'Brien stayed on in an advisory capacity into May to smooth the handover, an orderly transition, in the language of the ASX release, rather than a defenestration.
The board also got smaller on purpose. Non-executive directors Patrick Blake and Anne Lockwood departed after the February half-year results, and Mayne was explicit that streamlining was in shareholders' interests. A bloated, deal-era board makes sense when you are being acquired and every committee needs a seat; it makes far less sense for a standalone company trying to cut costs and move quickly. Shrinking the table is both a governance decision and a message about where the company thinks it is heading.
Then came the piece that points at the future. In June, Mayne appointed Meghan Rivera, a US pharmaceuticals executive with more than 25 years in the market, a former US president at Organon and currently a global commercial lead at ViiV Healthcare. Her background sits squarely in women's health and US commercialisation precisely the franchise Mayne has flagged as its crown jewel, and precisely the operation the company has been weighing whether to sell or spin off to claw back value for shareholders. You don't recruit that profile to mind an Australian manufacturing base. You recruit it when the strategic centre of gravity is a US business you intend to grow, sell, or dress up for a buyer.
Not every exit was a wound, either. Director Kathryn MacFarlane left in May to become chief executive of a US biopharma company, a reminder that in a churny period, some departures are simply good people getting promoted elsewhere, and a board that treats every resignation as a crisis will misread its own story.
The wider pattern
Mayne is a vivid case, but it is not an outlier. Early 2026 was an unusually busy season for ASX boardrooms. One market data scan counted around 93 individual director movements across more than 60 listed companies in roughly three weeks spanning February and March close to 1.5 times the normal run rate. Some of that is calendar mechanics, with boards refreshing around half-year results. Some of it is genuine turbulence.
The trick for investors is telling repair from routine. When a stable operator adds a single experienced non-executive director, that is maintenance — capability layered onto a business that is working. When the top of the house empties at once, it is something else. Seven West Media lost its chief executive, its interim chairman and a director within days of each other in February before appointing a new non-executive director in March. That near-simultaneous clear-out at the summit is the governance equivalent of a smoke alarm. It usually means one of three things: an acquisition handover, a loss of board confidence, or a company resetting under real financial strain.
Good rebuilding, as opposed to mere reshuffling, has a recognisable shape. The Governance Institute and the ASX Corporate Governance Principles both push boards toward a skills-matrix discipline — mapping the expertise you actually need against the strategy you are actually pursuing, then filling the gaps rather than replacing bodies like-for-like. A healthcare board that has just decided its future is a US commercial one should be adding US commercial firepower. On that test, Rivera's appointment is coherent in a way that a lot of post-crisis appointments are not.
The part appointments can't fix
Here is the uncomfortable truth a board reshuffle cannot paper over. Mayne's underlying earnings have been soft, with first-half FY26 EBITDA down and dragged by a large non-cash write-down on the very women's health portfolio it is banking on. The company is still carrying legal costs from the Cosette fight and still weighing a break-up of its own operations. New directors and a promoted CEO do not, by themselves, sell a product or lift a share price.
That is the honest verdict on board rebuilding after leadership churn: it is necessary, and it is nowhere near sufficient. You can reconstitute a board in an afternoon and announce it before market open. Rebuilding the trust of a bruised share register takes quarters of delivery, not a single ASX release. Mayne has assembled a board that says the right things about continuity, cost and a US-facing future. Whether Aaron Gray's team can turn that architecture into earnings is the only signal that will ultimately matter and it is the one no appointment can send in advance.
At Inspirepreneurs Magazine, covering entrepreneurship, business failures, and the human stories behind the world's most ambitious founders. She writes at the intersection of strategy and storytelling.
